Paul Hopper - Net Worth and Insider Trading

Paul Hopper Net Worth

The estimated net worth of Paul Hopper is at least $16,160 dollars as of 2024-04-26. Paul Hopper is the Director of EyePoint Pharmaceuticals Inc and owns about 1,000 shares of EyePoint Pharmaceuticals Inc (EYPT) stock worth over $16,160. Details can be seen in Paul Hopper's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Paul Hopper has not made any transactions after 2012-10-01 and currently still holds the listed stock(s).

Transaction Summary of Paul Hopper

To

Paul Hopper Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Paul Hopper owns 3 companies in total, including EyePoint Pharmaceuticals Inc (EYPT) , Fibrocell Science Inc (FCSC) , and Scopus BioPharma Inc (SCPS) .

Click here to see the complete history of Paul Hopper’s form 4 insider trades.

Insider Ownership Summary of Paul Hopper

Ticker Comapny Transaction Date Type of Owner
EYPT EyePoint Pharmaceuticals Inc 2012-10-01 director
FCSC Fibrocell Science Inc 2009-09-25 director
SCPS Scopus BioPharma Inc 2020-12-15 director

Paul Hopper Latest Holdings Summary

Paul Hopper currently owns a total of 1 stock. Paul Hopper owns 1,000 shares of EyePoint Pharmaceuticals Inc (EYPT) as of October 1, 2012, with a value of $16,160.

Latest Holdings of Paul Hopper

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
EYPT EyePoint Pharmaceuticals Inc 2012-10-01 1,000 16.16 16,160

Holding Weightings of Paul Hopper


Paul Hopper Form 4 Trading Tracker

According to the SEC Form 4 filings, Paul Hopper has made a total of 0 transactions in EyePoint Pharmaceuticals Inc (EYPT) over the past 5 years. The most-recent trade in EyePoint Pharmaceuticals Inc is the acquisition of 1,000 shares on October 1, 2012, which cost Paul Hopper around $16,200.

Insider Trading History of Paul Hopper

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Paul Hopper Trading Performance

GuruFocus tracks the stock performance after each of Paul Hopper's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul Hopper is -25.31%. GuruFocus also compares Paul Hopper's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul Hopper within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Paul Hopper's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Paul Hopper

Average Return

232.1%

Average return per transaction

Outperforming Transactions

100%

2 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -4.32 -25.31 46.91 232.1 58.11 30.37
Relative Return to S&P 500(%) -3.15 -24.04 38.76 214.76 42.04 20.35

Paul Hopper Ownership Network

Ownership Network List of Paul Hopper

No Data

Ownership Network Relation of Paul Hopper


Paul Hopper Owned Company Details

What does EyePoint Pharmaceuticals Inc do?

Who are the key executives at EyePoint Pharmaceuticals Inc?

Paul Hopper is the director of EyePoint Pharmaceuticals Inc. Other key executives at EyePoint Pharmaceuticals Inc include SVP & Chief Commercial Officer David Scott Jones , Chief Medical Officer Dario A. Paggiarino , and director & President and CEO Nancy Lurker .

EyePoint Pharmaceuticals Inc (EYPT) Insider Trades Summary

Over the past 18 months, Paul Hopper made no insider transaction in EyePoint Pharmaceuticals Inc (EYPT). Other recent insider transactions involving EyePoint Pharmaceuticals Inc (EYPT) include a net sale of 943,936 shares made by Ew Healthcare Partners, L.p. , a net sale of 121,307 shares made by Dario A. Paggiarino , and a net purchase of 3,944,057 shares made by Cormorant Asset Management, Lp .

In summary, during the past 3 months, insiders sold 209 shares of EyePoint Pharmaceuticals Inc (EYPT) in total and bought 581,765 shares, with a net purchase of 581,556 shares. During the past 18 months, 4,194,936 shares of EyePoint Pharmaceuticals Inc (EYPT) were sold and 3,944,057 shares were bought by its insiders, resulting in a net sale of 250,879 shares.

EyePoint Pharmaceuticals Inc (EYPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

EyePoint Pharmaceuticals Inc Insider Transactions

No Available Data

Paul Hopper Mailing Address

Above is the net worth, insider trading, and ownership report for Paul Hopper. You might contact Paul Hopper via mailing address: 7982 Doug Hill, San Diego Ca 92127.

Discussions on Paul Hopper

No discussions yet.